Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 5:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,548 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Stem Cell Transplant Patients Clear all
Recruiting Not applicable Interventional

CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT

NCT03810196
View directory record Official record
Conditions
Acute Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Lymphoblastic Leukemia, Mixed Lineage Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma, Juvenile Myelomonocytic Leukemia
Interventions
CliniMACS Cell Processing System for TCRαβ + T Cell and CD45RA Depleted Peripheral Stem Cell Addback
Device
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 25 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 20, 2026, 5:49 PM EDT
Terminated Phase 3 Interventional

Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation

NCT00003056
View directory record Official record
Conditions
Leukemia, Lymphoma, Graft Versus Host Disease
Interventions
cyclosporine, cyclosporine and methotrexate
Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2003
U.S. locations
12
States / cities
Los Angeles, California • Jacksonville, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Sep 20, 2026, 5:49 PM EDT
Completed Phase 1 Interventional Results available

Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin

NCT01175356
View directory record Official record
Conditions
Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
Interventions
3-Dimensional Conformal Radiation Therapy, Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Cisplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide Phosphate, External Beam Radiation Therapy, In Vitro-Treated Peripheral Blood Stem Cell Transplantation, Intensity-Modulated Radiation Therapy, Iobenguane I-131, Isotretinoin, Laboratory Biomarker Analysis, Melphalan, Pharmacological Study, Questionnaire Administration, Therapeutic Conventional Surgery, Topotecan Hydrochloride, Vincristine Sulfate
Radiation · Procedure · Drug + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 30 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2025
U.S. locations
25
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 20, 2026, 5:49 PM EDT
Completed Phase 2 Interventional Results available

Multi-day Doses in Prevention of Nausea and Emesis

NCT00600353
View directory record Official record
Conditions
Myeloma, Plasma-Cell, Lymphoma, Malignant
Interventions
Palonosetron, Aprepitant, Dexamethasone
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Sep 20, 2026, 5:49 PM EDT
Completed Phase 2 Interventional Results available

Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic Cancers

NCT00619645
View directory record Official record
Conditions
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
busulfan, cyclosporine, fludarabine phosphate, mycophenolate mofetil, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Drug · Procedure
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 120 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 9, 2018 · Synced Sep 20, 2026, 5:49 PM EDT
Completed Phase 2 Interventional Results available

Fludarabine / Total Body Irradiation Regimen for ALLO HCT in Acute Lymphoblastic Leukemia

NCT01991457
View directory record Official record
Conditions
Adult Lymphoblastic Lymphoma
Interventions
Fludarabine, Total Body Irradiation
Drug · Procedure
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
40 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 11, 2024 · Synced Sep 20, 2026, 5:49 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Followed by Bone Marrow and/or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Medulloblastoma or CNS Germ Cell Tumors

NCT00002594
View directory record Official record
Conditions
Brain Tumor, Central Nervous System Tumor
Interventions
Sargramostim, cyclophosphamide, melphalan, autologous bone marrow transplantation, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
2 Years to 25 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2007
U.S. locations
103
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 80 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2014 · Synced Sep 20, 2026, 5:49 PM EDT
Completed Not applicable Interventional

Study of Total Body Irradiation and Fludarabine Followed By Allogeneic Peripheral Blood Stem Cell or Bone Marrow Transplantation in Combination With Cyclosporine and Mycophenolate Mofetil in Patients With Inherited Disorders

NCT00010361
View directory record Official record
Conditions
Metabolism, Inborn Errors, Granulomatous Disease, Chronic
Interventions
cyclosporine, fludarabine, mycophenolate mofetil
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 8, 2014 · Synced Sep 20, 2026, 5:49 PM EDT
Completed Not applicable Interventional

Study of the Emotional Needs of Caregivers of Stem Cell Transplantation Patients

NCT00082654
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Neuroblastoma, Ovarian Cancer, Psychosocial Effects of Cancer and Its Treatment, Testicular Germ Cell Tumor
Interventions
psychosocial assessment and care
Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 20, 2010 · Synced Sep 20, 2026, 5:49 PM EDT
Completed Phase 1 Interventional

Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Cell Lymphoma After Autologous Transplant

NCT00434629
View directory record Official record
Conditions
B-cell Lymphoma, Non-Hodgkin's Lymphoma
Interventions
Bexxar
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 16, 2016 · Synced Sep 20, 2026, 5:49 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Biological Therapy in Treating Patients With Solid Tumors or Lymphoma

NCT00027937
View directory record Official record
Conditions
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
aldesleukin, filgrastim, sargramostim, busulfan, cyclophosphamide, melphalan, paclitaxel, thiotepa, bone marrow ablation with stem cell support, in vitro-treated peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 56 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 13, 2010 · Synced Sep 20, 2026, 5:49 PM EDT
Completed Phase 3 Interventional

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage II or Stage IIIA Breast Cancer

NCT00003972
View directory record Official record
Conditions
Breast Cancer
Interventions
filgrastim, sargramostim, busulfan, carboplatin, cyclophosphamide, melphalan, paclitaxel, tamoxifen citrate, thiotepa, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 1, 2010 · Synced Sep 20, 2026, 5:49 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies

NCT02743351
View directory record Official record
Conditions
Hematologic Malignancies, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, Acute Graft-versus-host Disease
Interventions
ProTmune, Control Arm
Biological
Lead sponsor
Fate Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
15
States / cities
Birmingham, Alabama • Duarte, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Sep 20, 2026, 5:49 PM EDT
Completed Phase 2 Interventional Results available

Reduced Intensity Conditioning Using CD3+/CD19+ Depletion for Non Malignant Transplantable Diseases

NCT02277639
View directory record Official record
Conditions
Bone Marrow Failure Syndromes, Immunodeficiencies, Immune Dysregulation Syndromes
Interventions
CliniMACs device
Device
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 22 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 10, 2018 · Synced Sep 20, 2026, 5:49 PM EDT
Completed Phase 4 Interventional

A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT

NCT03176849
View directory record Official record
Conditions
Vitamin D Deficiency, Stem Cell Transplant Complications, Pediatric Cancer, Blood Disorder, Pediatric Acute Myeloid Leukemia, Pediatric Acute Lymphoid Leukemia, Myelodysplastic Syndromes, Sickle Cell Anemia in Children, Aplastic Anemia, Thalassemia in Children
Interventions
Vitamin D3, Standard Vitamin D3 Supplementation
Dietary Supplement
Lead sponsor
Phoenix Children's Hospital
Other
Eligibility
1 Year to 25 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Sep 20, 2026, 5:49 PM EDT
Completed Not applicable Interventional Results available

The "Light for the Brain" Study

NCT02677987
View directory record Official record
Conditions
Hematopoietic Stem Cell Transplantation, Cognitive Impairments, Sleep, Depression, Fatigue, Quality of Life
Interventions
Intervention systematic light exposure, Comparison systematic light exposure
Device
Lead sponsor
Northwestern University
Other
Eligibility
21 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 17, 2022 · Synced Sep 20, 2026, 5:49 PM EDT
Recruiting Not applicable Interventional

Prehabilitation Program to Improve Cardiac Reserve in High-Risk Patients Undergoing Hematopoietic Stem Cell Transplantation

NCT05945121
View directory record Official record
Conditions
Hematopoietic Stem Cell Transplant
Interventions
Cardio-oncology program
Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 20, 2026, 5:49 PM EDT
Active, not recruiting Phase 1 Interventional

90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome

NCT05139004
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Basiliximab, Fludarabine Phosphate, Indium In 111-DOTA-Basiliximab, Melphalan, Palifermin, Total Lymphoid Irradiation, Total Marrow Irradiation, Yttrium Y 90 Basiliximab
Procedure · Biological · Drug + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
60 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 20, 2026, 5:49 PM EDT
Active, not recruiting Phase 3 Interventional

Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission

NCT03267433
View directory record Official record
Conditions
Mantle Cell Lymphoma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy, Computed Tomography, Positron Emission Tomography, Rituximab, Rituximab and Hyaluronidase Human
Procedure · Biological
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years to 70 Years
Enrollment
689 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
374
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 236 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 20, 2026, 5:49 PM EDT
Terminated Phase 1 Interventional

Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma

NCT05065047
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Belantamab mafodotin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Sep 20, 2026, 5:49 PM EDT
Completed Phase 3 Interventional Results available

A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)

NCT02312258
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Placebo, Ixazomib
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
706 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
23
States / cities
Fountain Valley, California • Los Angeles, California • Oceanside, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Sep 20, 2026, 5:49 PM EDT
Completed Phase 1 Interventional Results available

Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

NCT01798004
View directory record Official record
Conditions
Ganglioneuroblastoma, Stage 1 Neuroblastoma, Stage 2 Neuroblastoma, Stage 2A Neuroblastoma, Stage 2B Neuroblastoma, Stage 3 Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Cisplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, External Beam Radiation Therapy, Filgrastim, Laboratory Biomarker Analysis, Melphalan, Mesna, Peripheral Blood Stem Cell Transplantation, Pharmacological Study, Topotecan Hydrochloride, Vincristine Sulfate
Procedure · Drug · Radiation + 2 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
113
States / cities
Birmingham, Alabama • Downey, California • Duarte, California + 90 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2024 · Synced Sep 20, 2026, 5:49 PM EDT
Completed Not applicable Interventional Results available

Partially Matched Stem Cell Transplantation for Patients With Refractory Severe Aplastic Anemia or Refractory Cytopenias

NCT00244010
View directory record Official record
Conditions
Anemia, Aplastic, Amegakaryocytic Thrombocytopenia, Diamond-Blackfan Anemia, Kostmann Syndrome
Interventions
Allogeneic stem cell transplant
Device
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 20, 2026, 5:49 PM EDT
Terminated No phase listed Observational

Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous Leukemia (CML)

NCT00185523
View directory record Official record
Conditions
Leukemia, Lymphocytic, Acute, Leukemia, Leukemia Acute Promyelocytic Leukemia (APL), Leukemia Acute Lymphoid Leukemia (ALL), Leukemia Chronic Myelogenous Leukemia (CML), Leukemia Acute Myeloid Leukemia (AML), Leukemia Chronic Lymphocytic Leukemia (CLL)
Interventions
Allogeneic hematopoietic cell transplantation
Procedure
Lead sponsor
Stanford University
Other
Eligibility
4 Weeks to 55 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 15, 2016 · Synced Sep 20, 2026, 5:49 PM EDT